Dashboard
Manage Tickers

SNYSanofi

Nasdaq sanofi.com


$ 50.63 $ 0.26 (0.52 %)    

Friday, 19-Jul-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 475.02 $ -4.25 (-0.89 %)
DIA $ 402.92 $ -3.77 (-0.93 %)
SPY $ 548.99 $ -3.67 (-0.66 %)
TLT $ 92.97 $ -0.55 (-0.59 %)
GLD $ 221.79 $ -4.05 (-1.79 %)
$ 50.62
$ 50.13
$ 49.61 x 100
$ 50.83 x 237
$ 50.02 - $ 50.63
$ 40.90 - $ 53.45
2,087,312
na
63.6B
$ 0.58
$ 10.65
TBD
na
na ($ 0.08)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

european-commission-faces-court-criticism-over-covid-vaccine-contract-transparency-ahead-of-vote-on-ursula-von-der-leyens-reappointment
European Commission Faces Court Criticism ...
07/17/2024 18:24:05

European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implication...

sanofis-consumer-arm-said-to-draw-bids-from-advent-pai-cdr---bloomberg
'Sanofi's Consumer Arm Said to Draw Bids F...
07/17/2024 12:16:09

Private equity firms Advent International and PAI Partners are among suitors that submitted first-round offers for French drugm...

senate-to-review-novo-nordisks-levemir-insulin-discontinuation
Senate To Review Novo Nordisk's Levemir In...
07/16/2024 17:49:39

Novo Nordisk will meet with U.S. Senate aides to discuss the discontinuation of Levemir, its long-acting insulin, amid concerns...

sanofis-20b-consumer-health-unit-sale-goldman-sachs-morgan-stanley-line-up-65b-financing
Sanofi's $20B Consumer Health Unit Sale: G...
07/12/2024 18:39:18

Explore the €6 billion financing effort by banks for Sanofi's consumer health division sale. Discover the latest in high-st...

banks-planning-6b-debt-financing-for-sanofi-consumer-unit-sale
Banks Planning €6B Debt Financing For Sano...
07/12/2024 15:21:00

- Bloomberg

bernie-sanders-targets-high-prices-of-ozempic-and-wegovy-in-us
Bernie Sanders Targets High Prices of Ozem...
07/11/2024 17:47:17

Senator Bernie Sanders is pushing Novo Nordisk to lower U.S. prices for weight-loss drugs Ozempic and Wegovy, as part of a broa...

sanofi-ships-us-influenza-vaccines-for-202425-season
Sanofi Ships U.S. Influenza Vaccines For 2...
07/10/2024 20:12:02

Customers will start receiving shipments from July 10 with additional shipments through October to healthcare provider offices,...

sanofi-ceo-says-talking-to-private-equity-for-sale-of-consumer-arm
Sanofi CEO Says Talking To Private Equity ...
07/03/2024 15:59:43

- Bloomberg

europe-approves-sanofiregenerons-dupixent-for-smokers-lungs-a-month-after-us-fda-asks-for-data
Europe Approves Sanofi/Regeneron's Dupixen...
07/03/2024 12:55:42

EMA approves Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised ...

heartburn-drug-zantac-litigation-gsk-and-other-pharma-giants-face-trial-over-cancer-claims
Heartburn Drug Zantac Litigation: GSK And ...
07/02/2024 12:39:03

A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to...

sanofi-nears-decision-on-16b-upgrade-for-frankfurt-insulin-plant
Sanofi Nears Decision on $1.6B Upgrade For...
07/01/2024 15:13:28

Sanofi is set to invest up to $1.6 billion in its Frankfurt insulin production site, marking a significant win for Germany'...

sanofis-frexalimab-phase-2-data-shows-41-reduction-in-key-biomarker-of-nerve-cell-damage-in-relapsing-ms-high-dose-arm-demonstrates-significant-drop-in-plasma-neurofilament-light-chain-levels-after-48-weeks-supports-potential-as-high-efficacy-disease-modifying-treatment-phase-3-studies-underway
Sanofi's Frexalimab Phase 2 Data Shows 41%...
06/28/2024 15:41:36

Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MSFrexalimab high-dose arm obse...

Core News & Articles
CDC's ACIP Unanimously Votes To Add Merck ...
06/27/2024 19:40:39

- Reuters

first-inhaled-copd-therapy-in-over-2-decades---fda-approves-verona-pharmas-first-commercial-product
First Inhaled COPD Therapy In Over 2 Decad...
06/27/2024 13:49:19

The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary dis...

Core News & Articles
Vigil Neuroscience Secures $40M from Sanof...
06/27/2024 06:59:38

Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia f...

Core News & Articles
Regeneron, Sanofi Present Phase 3 Trial Fo...
06/26/2024 21:34:07

The trial showed a greater proportion of those receiving weight-tiered higher dose Dupixent experienced significant improvement...

sanofi-looks-to-sell-20b-icy-hot-division-likely-bidders-include-advent-pai-partners-blackstone-cvc
Sanofi Looks To Sell $20B Icy Hot Division...
06/26/2024 13:16:58

Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.

tuesday-sanofi-announced-riliprubart-one-year-follow-up-from-phase-2-study-showed-efficacy-and-safety-and-rapid-and-durable-reduction-of-key-biomarkers-including-those-associated-with-classical-complement-pathway-and-nerve-cell-damage
Tuesday Sanofi Announced Riliprubart One-y...
06/26/2024 10:49:20

https://www.sanofi.com/en/media-room/press-releases/2024/2024-06-25-20-30-00-2904145

sanofi-seeks-bids-for-20b-consumer-arm-by-mid-july-advent-pai-among-top-suitors-blackstone-cdr-cvc-and-tpg-also-interested
Sanofi Seeks Bids For $20B Consumer Arm By...
06/25/2024 16:53:31

- Bloomberg Citing Sources

sanofi-to-present-altuviiios-long-term-efficacy-and-fitusirans-prophylaxis-potential-at-isth
Sanofi To Present ALTUVIIIO's Long-Term Ef...
06/21/2024 05:42:03

ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran Seven oral presentations across the...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)
07/30/2024 Rivian Automotive, Inc. (RIVN)
07/30/2024 Hertz Global Holdings, Inc. (HTZ)
08/02/2024 Humana Inc. (HUM)
08/05/2024 Marinus Pharmaceuticals, Inc. (MRNS)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)